Objective Influenza is a recurrent global threat and affects millions of people in Europe and the world every year. The Universal Vaccine project is highly original and brings together European state-of-the-art scientists in order to develop a powerful new mucosal vaccine for humans providing life-long protection against influenza. In the longer perspective, the project may contribute to the objective of reducing or even eradicating influenza disease in humans.The Universal Vaccine project combines European SMEs and RTD performers that have pioneered the development of new vaccines and vaccine formulations, and which possess unique IPR related to new components and procedures that can be used for safer and more effective vaccination strategies. Arexis (SE) is the IPR holder of CTA1-DD, which is a new highly potent mucosal adjuvant. Pepscan (NL) has unique knowledge and IPR related to peptides and peptidomimetics while Proxima Concepts (UK) has the exclusive IPR related to a proprietary delivery technology. The unique collaboration between these SMEs and VIB/University of Ghent (BE), the IP holder of M2e-based influenza vaccines, Eurogentec (BE) and Göteborg University (SE) has the potential of resulting in important breakthroughs in European vaccine development research.The unique combination of the three SMEs for the rational design of a mucosal influenza vaccine is unprecedented in European vaccine research. A successful novel mucosal vaccine against influenza would have significant impact on the global market and secure the growth and development of the European vaccine industry. If successful, Arexis, Pepscan and Proxima will establish themselves firmly on the market for mucosal vaccines, and their extended and potentially stronger IP would allow for an expansion of their respective business markets. Fields of science natural sciencesbiological sciencesmicrobiologyvirologynatural sciencesbiological sciencesbiochemistrybiomoleculesproteinsmedical and health scienceshealth sciencesinfectious diseasesRNA virusesinfluenzamedical and health sciencesbasic medicineimmunologymedical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsvaccines Programme(s) FP6-SME - Horizontal research activities involving SMEs: Specific activities covering wider field of research under the Focusing and Integrating Community Research programme 2002-2006. Topic(s) SME-1 - Co-operative Research (all areas of science and technology) Call for proposal FP6-2003-SME-1 See other projects for this call Funding Scheme Cooperative - SMEs-Co-operative research contracts Coordinator BIOVITRUM AB EU contribution No data Address Arvid Wallgrens Backe 20 GÖTEBORG Sweden See on map Links Website Opens in new window Total cost No data Participants (6) Sort alphabetically Sort by EU Contribution Expand all Collapse all AREXIS AB Sweden EU contribution No data Address Arvid Wallgrens Backe 20 GÖTEBORG See on map Links Website Opens in new window Total cost No data EUROGENTEC SA Belgium EU contribution No data Address Rue Bois Saint Jean 5, Liege Science Park, SERAING See on map Links Website Opens in new window Total cost No data GÖTEBORG UNIVERSITY Sweden EU contribution No data Address Vasaparken GÖTEBORG See on map Links Website Opens in new window Total cost No data PEPSCAN SYSTEMS B.V. Netherlands EU contribution No data Address Edelhertweg 15 2098 LELYSTAD See on map Links Website Opens in new window Total cost No data PROXIMA CONCEPTS LTD United Kingdom EU contribution No data Address c/o London BioScience Innovation Centre, 2 Royal College Street LONDON See on map Links Website Opens in new window Total cost No data VLAAMS INTERUNIVERSITAIR INSTITUUT VOOR BIOTECHNOLOGIE, VZW Belgium EU contribution No data Address Rijvisschestraat 120 ZWIJNAARDE See on map Links Website Opens in new window Total cost No data